Aggressive and indolent non-Hodgkin's lymphoma: Response assessment by Integrated International Workshop Criteria

References

• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. J Clin Oncol 1999; 17: 1244–1253
   PubMed Web of Science ®Google Scholar
• Coiffier B. How to interpret the radiological abnormalities that persist after treatment in non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10: 1141–1143
   PubMed Web of Science ®Google Scholar
• Spaepen K, Stroobants S, Dupont P, Van Steenweghen S, Thomas J, Vandenberghe P, et al. Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods?. J Clin Oncol 2001; 19: 414–419
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Fassotte M F, Najjar F, Paulus P, Rigo P, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for post-treatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed classical computed tomography scan imaging. Blood 1999; 94: 429–433
   PubMed Web of Science ®Google Scholar
• Naumann R, Vaic A, Beuthien-Baumann B, Bredow J, Kropp J, Kittner T, et al. Prognostic value of positron emission tomography in the evaluation of post-treatment residual mass in patients with Hodgkin's disease and non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 793–800
   PubMed Web of Science ®Google Scholar
• Zinzani P L, Fanti S, Battista G, Tani M, Castellucci P, Stefoni V, et al. Predictive role of positron emission tomography (PET) in the outcome of lymphoma patients. Br J Cancer 2004; 91: 850–854
   PubMed Web of Science ®Google Scholar
• Mikhaeel N G, Timothy A R, O'Doherty M J, Hain S, Maisey M N. 18-FDG-PET as a prognostic indicator in the treatment of aggressive Non-Hodgkin's lymphoma – comparison with CT. Leuk Lymphoma 2000; 39: 543–553
   PubMed Web of Science ®Google Scholar
• Cheson B D, Pfistner B, Juweid M E, Gascoyne R D, Specht L, Horning S J, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007; 25: 579–586
   PubMed Web of Science ®Google Scholar
• Juweid M E, Stroobants S, Hoekstra O S, Mottaghy F M, Dietlein M, Guermazi, et al. Use of positron emission tomography (PET) for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project (IHP) in Lymphoma. J Clin Oncol 2007; 25: 571–578
   PubMed Web of Science ®Google Scholar
• Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi Y E, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 4643–4651
   PubMed Web of Science ®Google Scholar
• Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte M F, Rigo P, et al. Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin's lymphoma (NHL). Ann Oncol 2001; 12: 825–830
   PubMed Web of Science ®Google Scholar
• Najjar F, Hustinx R, Jerusalem G, Fillet G, Rigo P. Positron emission tomography (PET) for staging low-grade non-Hodgkin's lymphomas (NHL). Cancer Biother Radiopharm 2001; 16: 297–304
   PubMed Web of Science ®Google Scholar
• Barosi G, Carella A, Lazzarino M, Marchetti M, Martelli M, Rambaldi A, et al. Management of nodal indolent (non marginal-zone) non-Hodgkin's lymphomas: practice guidelines from the Italian Society of Hematology, Italian Society of Experimental Hematology and Italian Group for Bone Marrow Transplantation. Haematologica 2005; 90: 1236–1257
   PubMed Web of Science ®Google Scholar
• Armitage J. Staging Non-Hodgkin lymphoma. CA Cancer J Clin 2005; 55: 368–376
   PubMed Web of Science ®Google Scholar
• Harris N L, Jaffe E S, Stein H, Banks P M, Chan J K, Cleary M L, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84: 1361–1392
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Atra A, Imeson J D, Hobson R, Gerrard M, Hann I M, Eden O B, et al. Improved outcome in children with advanced stage B-cell non-Hodgkin's lymphoma (B-NHL): results of the United Kingdom Children Cancer Study Group (UKCCSG) 9002 protocol. Br J Cancer 2000; 82: 1396–1402
   PubMed Web of Science ®Google Scholar
• Kaplan E S, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58: 457–481
   Google Scholar
• Freudenberg L S, Antoch G, Schutt P, Beyer T, Jentzen W, Muller S P, et al. FDG-PET/CT in re-staging of patients with lymphoma. Eur J Nucl Med Mol Imaging 2004; 31: 325–329
   PubMed Web of Science ®Google Scholar